CryoLife (AORT): Market Cap to Revenue

The company's price-to-sales ratio demonstrates the resilience of Artivion, Inc. (AORT) driven by global sales of bioprostheses and vascular adhesives. The current status is 1.90. R&D expenses and the risk of product quality litigation are weighing on the dynamics. Stability is further supported by a standardized approach to biomaterial utilization and strict adherence to sterility standards.
Analytical breakdowns for artivion.com (AORT)

Artivion, Inc. (AORT) operates as a developer of high-tech cardiac surgery devices, which necessitates significant investment in biomedical capital and stringent quality control. An analysis of the median P/S ratio, reflecting the relationship between market capitalization and annual revenue, allows for the determination of the asset's overvaluation relative to its fundamental earnings and helps identify optimal entry points or the need to hedge against downside risks.